SCHEMBL4364907

SCHEMBL4364907

Cc1ccccc1Oc1ncnc2ccccc12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.59
CYP2C19 P33261 3/20 0.59
MRGPRX1 Q96LB2 2/20 0.59
SMN1; SMN2 Q16637 3/20 0.52
CYP2C9 P11712 2/20 0.52
MAPT P10636 2/20 0.52
KDM4E B2RXH2 2/20 0.52
ALDH1A1 P00352 2/20 0.52
HPGD P15428 2/20 0.52
GAA P10253 1/20 0.52
MCHR1 Q99705 1/20 0.52
EGFR P00533 2/20 0.51
RAB9A P51151 3/20 0.49
NPC1 O15118 2/20 0.49
TSHR P16473 2/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
MAP4K4 O95819 1/20 0.48
KDR P35968 1/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3635988 0.83 EGFR (0.62) CYP1A2CYP2C19SMN1; SMN2CYP2C9EGFR
SCHEMBL31514571 0.82 CYP1A2 (0.51) CYP1A2CYP2C19MRGPRX1SMN1; SMN2CYP2C9
SCHEMBL1591261 0.81 EGFR (0.50) CYP1A2CYP2C19CYP2C9MAPTKDM4E
SCHEMBL7641819 0.81 EGFR (0.50) CYP1A2CYP2C19MRGPRX1SMN1; SMN2CYP2C9
SCHEMBL3977060 0.78 EGFR (0.57) CYP1A2CYP2C19MRGPRX1SMN1; SMN2CYP2C9
SCHEMBL4255718 0.78 EGFR (0.50) CYP1A2CYP2C19CYP2C9MAPTALDH1A1
SCHEMBL3979754 0.77 EGFR (0.69) CYP1A2CYP2C19CYP2C9MAPTKDM4E
SCHEMBL4766092 0.76 RAB9A (0.46) CYP1A2CYP2C19MRGPRX1SMN1; SMN2RAB9A
SCHEMBL30117773 0.76 RAB9A (0.56) CYP1A2CYP2C19SMN1; SMN2CYP2C9MAPT
SCHEMBL7053228 0.76 RAB9A (0.56) CYP1A2CYP2C19SMN1; SMN2CYP2C9MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090291971-A1 HETEROARYL ETHERS AND PROCESSES FOR THEIR PREPARATION WYETH (US) 2009-11-26 US disclosed
US-20090291971-A1 HETEROARYL ETHERS AND PROCESSES FOR THEIR PREPARATION WYETH (US) 2009-11-26 US disclosed
US-20090291971-A1 HETEROARYL ETHERS AND PROCESSES FOR THEIR PREPARATION WYETH (US) 2009-11-26 US disclosed
WO-2009058937-A2 HETEROARYL ETHERS AND PROCESSES FOR THEIR PREPARATION WYETH (US) 2009-05-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291971-A1 HETEROARYL ETHERS AND PROCESSES FOR THEIR PREPARATION AHR, MALT1, ABL1 CYP1A2 38/4885CYP2C19 211/4885MRGPRX1 2655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.